Lodisure 1mg Tablets For Cats (pack of 56)

Active ingredient:Amlodipine

Each tablet contains: Active substance:
Amlodipine 1.0 mg (equivalent to 1.4 mg amlodipine besilate)
Excipient: Brilliant blue FCF (E133) 1.0 mg

Target species
Cats
Indications for use
For the treatment of feline systemic hypertension.
Contraindications
Do not use in animals with severe hepatic disease.
Do not use in cases of known hypersensitivity to the active substance or any of the excipients.
Do not use in the case of cardiogenic shock and severe aortic stenosis.
Special warnings for each target species
In cats situational hypertension (also called white coat hypertension) occurs as a consequence of the in-clinic measurement process in an otherwise normotensive animal. In case of high stress levels measurement of systolic blood pressure may lead to incorrect diagnosis of hypertension. It is recommended that stable hypertension is confirmed by multiple and repeated measurement of systolic blood pressure on different days before commencing therapy.
In case of secondary hypertension it is important to establish primary cause and/or co-morbidities of hypertension, such as hyperthyroidism, chronic kidney disease and diabetes and to treat these conditions.
Continued administration of the product over an extended period of time should be in accordance with an ongoing benefit/risk evaluation, performed by the prescribing veterinarian that includes measurement of systolic blood pressure routinely during treatment (e.g. every 2 to 3 months). If needed dosages may be adjusted.
Special precautions for use in animals
Special caution is required in patients with hepatic disease as amlodipine is highly metabolised by the liver. Consequently amlodipine half-life may be prolonged and a lower dose may be required. As no studies have been conducted in animals with liver disease, use of the product in these animals should be based on a benefit-risk assessment by the attending veterinarian.
Older cats with severe hypertension and chronic kidney disease (CKD) may suffer from hypokalaemia as a result of their underlying disease. Administration of amlodipine may sometimes result in a decrease in serum potassium and chloride levels and could thus lead to exacerbation of hypokalaemia already present. Monitoring of those concentrations is recommended before and during treatment.
No animals with severe unstable CKD were included in the clinical trials. Use of the product in these animals should be based on a benefit-risk assessment by the attending veterinarian.
Because amlodipine may have slight negative inotropic effects, the use of the product in cardiac patients should be based on a benefit risk assessment by the veterinarian. Safety has not been tested in cats with known heart disease.
Animals weighing less than 2.5 kg were not included in the clinical trials. Animals weighing between 2-2.5 kg should be treated with caution and based on a benefit risk assessment by the responsible veterinarian.
Doses above 0.47 mg/kg body weight have not been examined in clinical trials with the product and should only be administered with caution and based on a benefit risk assessment by the attending veterinarian.
The tablets are flavoured. To avoid accidental ingestion, store tablets out of reach of animals.